| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 1/100-1/500 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | ATP pyrophosphate-lyase; CYA6; Ca(2 )-inhibitable adenylyl cyclase; EC 4.6.1.1; KIAA0422 |
| Entrez GeneID | 112; |
| WB Predicted band size | 130kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthesized peptide derived from internal of human ADCY5/6. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于ADCY5/6抗体的示例参考文献(注：部分文献为示例性描述，实际引用时需核实来源)：
---
1. **文献名称**: "ADCY5 Mutations in Familial Dyskinesia: Altered Protein Localization and Function"
**作者**: Chen YZ, et al.
**摘要**: 研究ADCY5基因突变与家族性运动障碍的关联，通过抗ADCY5抗体进行免疫组化和Western blot，发现突变导致蛋白在神经元中的异常定位及cAMP信号通路受损。
2. **文献名称**: "Development and Validation of a Monoclonal Antibody Targeting ADCY6 for Cancer Research"
**作者**: Smith JL, et al.
**摘要**: 开发并验证了一种高特异性抗ADCY6单克隆抗体，应用于胰腺癌组织样本的免疫荧光和流式细胞术，证实ADCY6在肿瘤微环境中的高表达及其与预后的相关性。
3. **文献名称**: "ADCY5-Mediated cAMP Signaling in Neuronal Hyperexcitability Disorders"
**作者**: Brown KA, et al.
**摘要**: 在小鼠模型中研究ADCY5对神经元兴奋性的调控，使用抗ADCY5抗体进行免疫沉淀和共聚焦显微镜观察，揭示其与离子通道蛋白的相互作用机制。
4. **文献名称**: "Adenylyl Cyclase 6 as a Therapeutic Target in Pulmonary Fibrosis"
**作者**: Nakamura T, et al.
**摘要**: 探讨ADCY6在肺纤维化中的作用，通过抗ADCY6抗体进行Western blot和免疫组化分析，发现抑制ADCY6可减轻纤维化相关信号通路激活。
---
**说明**：以上文献为示例，实际研究中需通过数据库(如PubMed、Google Scholar)检索真实文献。若需具体文章，建议使用关键词“ADCY5 antibody”或“ADCY6 antibody”结合研究领域(如神经科学、癌症)进一步筛选。
ADCY5 and ADCY6 are isoforms of the membrane-bound adenylate cyclase (AC) family, enzymes that catalyze the conversion of ATP to cyclic AMP (cAMP), a critical secondary messenger in cellular signaling. ADCY5 is predominantly expressed in the brain, striated muscle, and heart, and is implicated in regulating motor function, neurotransmission, and cardiac activity. Mutations in *ADCY5* are linked to hyperkinetic movement disorders, such as familial dyskinesia. ADCY6. widely expressed in tissues like the liver, adipose, and heart, plays roles in metabolic regulation, insulin sensitivity, and cardiac contractility. Both isoforms are activated by G-protein-coupled receptors (GPCRs) and modulated by factors like calcium and protein kinases.
Antibodies targeting ADCY5/6 are essential tools for studying their expression, localization, and function. These antibodies are validated for applications including Western blotting, immunohistochemistry, and immunofluorescence, enabling researchers to explore tissue-specific distribution, disease-associated alterations, and signaling pathways. High specificity is critical due to structural homology among AC isoforms. ADCY5/6 antibodies have been instrumental in uncovering their roles in neurological disorders, metabolic syndromes, and cardiovascular diseases. Additionally, they aid in evaluating therapeutic targets, as aberrant cAMP signaling is implicated in conditions like obesity, diabetes, and arrhythmias. Commercial antibodies are typically raised against unique peptide sequences, with validation in knockout models to ensure reliability. Their use continues to advance understanding of cAMP-mediated mechanisms in health and disease.
×
